Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SUCNR1 siRNA
- Development stage
- Preclinical
- Lead developer
- UVEG
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
SUCNR1 siRNA is a small interfering RNA designed to silence the expression of the succinate receptor 1 (SUCNR1), also known as GPR91. SUCNR1 is a G protein-coupled receptor that responds to succinate, a metabolic intermediate that accumulates during hypoxia and inflammation. In the context of Crohn's disease, SUCNR1 activation has been linked to intestinal inflammation, fibrosis, and the development of fistulas by promoting epithelial-to-mesenchymal transition (EMT). By knocking down SUCNR1 expression, this siRNA inhibits succinate-induced fibrotic signaling and the expression of mesenchymal markers like Vimentin and Snail, suggesting that SUCNR1 inhibition could be a therapeutic strategy for treating fistulizing Crohn's disease.
- Other names
- succinate receptor 1 siRNAGPR91 siRNAGPR-91 siRNAGPR 91 siRNA
02
Targets
Innate immune RNA sensorsSUCNR1 (Succinate receptor 1)
Beyond the preview
Go deeper on SUCNR1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SUCNR1 siRNA.